Media headlines about TearLab Corporation (NASDAQ:TEAR) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TearLab Corporation earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 46.001715498567 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts have commented on TEAR shares. Rodman & Renshaw lowered their price objective on TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, May 16th. Zacks Investment Research upgraded TearLab Corporation from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Thursday, May 11th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of TearLab Corporation in a research report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $5.05.
TearLab Corporation (NASDAQ TEAR) opened at 2.17 on Wednesday. The stock’s 50 day moving average price is $2.03 and its 200-day moving average price is $3.14. TearLab Corporation has a 12 month low of $1.55 and a 12 month high of $8.30. The stock’s market cap is $12.44 million.
TearLab Corporation (NASDAQ:TEAR) last released its earnings results on Monday, May 15th. The medical research company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by $0.07. The firm had revenue of $6.70 million during the quarter, compared to analyst estimates of $7.02 million. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. Equities research analysts predict that TearLab Corporation will post ($2.82) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect TearLab Corporation (NASDAQ:TEAR) Stock Price” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/09/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-tearlab-corporation-nasdaqtear-stock-price.html.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.